Cerberus Therapeutics utilizes nanobody-based platform to create novel therapeutics for modulating the immune system.
The COVID-19 pandemic highlights the need for safe and accessible therapies to modulate our immune responses. We have developed strategies that allows for precise turning on/off the immune system in response to debilitating diseases.
Our pilot programs focus on autoimmune disorders and infectious diseases, that are based on novel biological discoveries originating from decades of work by our three founders: Dr. Novalia Pishesha, Prof. Hidde Ploegh, and Prof. Harvey Lodish.
Company Details
- Employees
- 8
- Founded
- -
- Address
- 700 Main St, Cambridge,massachusetts 02139,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.cerberustx.com/
- HQ
- Cambridge, Massachusetts
Cerberus Therapeutics Questions
Cerberus Therapeutics's website is https://www.cerberustx.com/
Cerberus Therapeutics's LinkedIn profile is https://www.linkedin.com/company/cerberus-therapeutics
Cerberus Therapeutics has
8 employees.
View email and phone details for 8
employees at Cerberus Therapeutics.
Cerberus Therapeutics's industry is
Biotechnology Research
Cerberus Therapeutics's top competitors are
Inndura Therapeutics,
Atavistik Bio,
Acousticabio,
Fletcher Biosciences,
Kano Therapeutics,
Gensaic,
Matrisome Bio,
Telesis Bio,
Rubik Therapeutics,
Transcera.
Cerberus Therapeutics's categories are Biotechnology Research
Cerberus Therapeutics's founding year is 2022
